關(guān)鍵詞： Raptor 罕見病 HealthCare Royalty Partners公司
2012年12月22日訊 /生物谷BIOON/ --HealthCare Royalty Partners公司繼贊助Nuron Biotech公司8000萬美元研究疫苗后,，又決定向Raptor Pharmaceutical提供高達(dá)5000萬美元的投資來贊助其罕見病治療項(xiàng)目,。而該項(xiàng)目將在2013年一月底迎來第一個截止日期,。
HC公司的投資將分為兩部分,，第一部分Raptor公司先獲得2500萬美元的資助用以研發(fā)其藥物Procysbi--商業(yè)名稱為RP103，該藥物旨在治療腎病型胱胺酸癥,，當(dāng)Procysbi獲得FDA的許可后,，HC公司將給予Raptor公司另外一半的資助。
Raptor 公司CEO Christopher Starr稱,，該項(xiàng)目將更充分的發(fā)掘Procysbi的價值并藉以獲得超過5500萬美元的收入,。（生物谷Bioon.com）
英文詳細(xì)報道：
Fast on the heels of its $80 million investment/royalty pact on Nuron Biotech's vaccine portfolio, HealthCare Royalty Partners agreed to lend Raptor Pharmaceutical ($RPTP) up to $50 million to help finance the prospective launch of its new drug for a rare metabolic disease, now facing a PDUFA deadline at the end of January.
Here's how the deal works: Raptor gets $25 million now and another $25 million if the FDA approves Procysbi, the commercial name for RP103 for the potential treatment of nephropathic cystinosis. The loans mature at the end of 2019 at a fixes rate of 10.75% and a "Synthetic Royalty" variable rate, tiered down, based on a percentage of future Procysbi sales. The loan is interest-only for the first two years.
"This loan agreement with HC Royalty further validates the growing value of Procysbi and Raptor's pipeline. We believe that the proceeds of this financing will provide us with the necessary capital to fund our activities through FDA approval of Procysbi, based on our current assumptions for the timing of a potential FDA approval of Procysbi, as well as to fund our plans to launch Procysbi in the U.S., if approved by the FDA," said Raptor CEO Christopher Starr in a statement. "At closing of the first Tranche we will have over $55 million in cash on our balance sheet, with an additional $25 million to be funded under the second tranche loan upon FDA approval of Procysbi."
